Fibrates and cholestasis

Cited by (318)

Items 201–300 of 318

1. Loureirin B ameliorates cholestatic liver fibrosis via AKT/mTOR/ATG7-mediated autophagy of hepatic stellate cells
   Wei‐Yi Cheng, Xi-xi Zeng, Ping Cheng, Jinxiang Zhang · 2024 · European Journal of Pharmacology
2. Swertia cincta and its main active ingredients regulate the PPAR-α pathway in anti-cholestatic liver injury
   Shuaixia Feng, Jie Tang, Xia Wei, Lu Zou, Ying Xin Xu, Tong Zhang, Han Han · 2024 · Journal of Ethnopharmacology
3. Therapeutic advances for primary biliary cholangitis: the old and the new
   Li Wang, Fengchun Zhang, Xuan Zhang · 2016 · European Journal of Gastroenterology & Hepatology
4. Current Therapies for Cholestatic Diseases
   Nahúm Méndez‐Sánchez, Carlos Esteban Coronel-Castillo, Ana Luisa Ordóñez-Vázquez · 2023 · Biomedicines
5. Engineered FGF19ΔKLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model
   Lu Shi, Tiantian Zhao, Lei Huang, Xiaomin Pan, Tianzhen Wu, Xin Feng, Taoli Chen, Jiamin Wu, Jianlou Niu · 2023 · BMC Biotechnology
6. The zhuyu pill relieves rat cholestasis by regulating the mRNA expression of lipid and bile metabolism associated genes
   Jun Han, Peijie Wu, Yueqiang Wen, Chao Liu, Xinglong Liu, Huan Tao, Fenghua Zhang, Xiaodan Zhang, Qiaobo Ye, Tao Shen et al. · 2023 · Frontiers in Pharmacology
7. Genetic variants of UDP‐glucuronosyltransferase 1A genes are associated with disease presentation and outcome in primary sclerosing cholangitis
   Tobias J. Weismüller, Taotao Zhou, Sandra Kalthoff, Henrike Lenzen, Michael Peter Manns, Christian P. Strassburg · 2020 · Liver International
8. miRNA and miRNA target genes in intervention effect of Zhuyu pill on cholestatic rat model
   Han Yu, Chao Liu, Jianfei Wang, Jun Han, Fenghua Zhang, Xin Zhou, Yueqiang Wen, Tao Shen · 2021 · Journal of Ethnopharmacology
9. Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis
   Zhigan Jiang, Xing Liu, Zhiliang Yuan, Haiying He, Jing Wang, Xiao Zhang, Zhen Long Gong, Lijuan Hou, Liang Shen, Fengxun Guo et al. · 2019 · ACS Medicinal Chemistry Letters
10. Investigational drugs in early phase development for primary biliary cholangitis
    Eric M. Gochanour, Kris V. Kowdley · 2020 · Expert Opinion on Investigational Drugs
11. Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity
    Francisco José Zapatero Belinchón, Rina Ötjengerdes, Julie Sheldon, Benjamin Schulte, Belén Carriquí-Madroñal, Graham Brogden, Laura M. Arroyo-Fernández, Florian W. R. Vondran, Benjamin Maasoumy, Thomas von Hahn et al. · 2021 · Cells
12. Advancing Second-Line Treatment for Primary Biliary Cholangitis
    David N. Assis · 2024 · New England Journal of Medicine
13. Primary biliary cholangitis: current insights and novel therapies
    Alessandro Granito, Γεώργιος Παππάς, Lucia Napoli, Benedetta Stefanini, Daniela Tirotta, Paolo Muratori · 2026 · Expert Review of Clinical Immunology
14. Quantitative proteomics reveals the protective effects of Yinchenzhufu decoction against cholestatic liver fibrosis in mice by inhibiting the PDGFRβ/PI3K/AKT pathway
    Qian Meng, Hongwen Zhu, Yuanyuan Li, Xiaotian Peng, Tianming Wang, Hui Huang, Hu Zhou, Yuejia Liu, Su-Jie Ru, Jiasheng Wu et al. · 2024 · Frontiers in Pharmacology
15. Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis
    Caines, Allyce, Trudeau, Sheri, Gordon, Stuart C. · 2024 · Expert Opinion on Pharmacotherapy
16. Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity
    Xiaochen Meng, Xiaoqian Li, Yi Gao, Shuyu Zhang · 2025 · Molecular Cancer
17. The effect of serum IL-2 levels on the prognosis of primary biliary cholangitis-related liver failure and the preliminary exploration of its mechanism
    Qi Wang, Yang Wang, Wenying Qiao, Bin Xu, Yanmin Liu, Xiaodan Zhang, Wenjuan Li, Juan Zhao, Mengcheng Liu, Yang Zhang et al. · 2022 · Frontiers in Immunology
18. Identifying hepatoprotective mechanism and effective components of Yinchenzhufu decoction in chronic cholestatic liver injury using a comprehensive strategy based on metabolomics, molecular biology, pharmacokinetics, and cytology
    Yuanyuan Li, Xiaotian Peng, Guofeng Wang, Bin Zan, Yahang Wang, Juan Zou, Tian Tian, Qian Meng, Rong Shi, Tianming Wang et al. · 2023 · Journal of Ethnopharmacology
19. Fibroblast growth factor 21 ameliorates cholestatic liver injury via a hepatic FGFR4-JNK pathway
    Chuanren Zhou, Xiaomin Pan, Lei Huang, Tianzhen Wu, Tiantian Zhao, Jie Qi, Jiamin Wu, Alan Vengai Mukondiwa, Yuli Tang, Yongde Luo et al. · 2023 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
20. Evolving role of obeticholic acid in primary biliary cholangitis
    Cynthia Levy · 2017 · Hepatology
21. Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies
    A. Curto, Rocco Gabriele Iamello, Erica Nicola Lynch, Andrea Galli · 2025 · World Journal of Clinical Cases
22. Gallstone and Gallbladder Disease: Biliary Tract and Cholangiopathies
    Ludovica Ceci, Yuyan Han, Kelsey Krutsinger, Leonardo Baiocchi, Nan Wu, Debjyoti Kundu, Konstantina Kyritsi, Tianhao Zhou, Eugenio Gaudio, Heather Francis et al. · 2023 · Comprehensive physiology
23. Lignans are the main active components of Schisandrae Chinensis Fructus for liver disease treatment: a review
    Ke Fu, Shu Dai, Cheng Ma, Yafang Zhang, Shenglin Zhang, Cheng Wang, Lihong Gong, Honglin Zhou, Yunxia Li · 2023 · Food Science and Human Wellness
24. Fibrates for Primary Biliary Cholangitis: What’s All the Hype?
    Cynthia Levy · 2017 · Annals of Hepatology
25. Pathologic Features of Hereditary Cholestatic Diseases
    Andrew Donald Clouston · 2018 · Surgical pathology clinics
26. Vitamin D3 suppresses the early stages of chemically induced hepatocarcinogenesis in rats: a dose-response analysis
    Mariana Baptista Tablas, Renata Leme Goto, Brunno Felipe Ramos Caetano, Sérgio Alexandre Alcântara dos Santos, Luı́s Fernando Barbisan · 2018 · Nutrire
27. Safety considerations for the management of cholestatic itch
    Juan Pablo Trivella, Cynthia Levy · 2021 · Expert Opinion on Drug Safety
28. Discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis
    Masaya Kanda, Mitsuhiro Goda, Akiko Maegawa, Toshihiko Yoshioka, Ami Yoshida, Kôji Miyata, Fuka Aizawa, Takahiro Niimura, Hirofumi Hamano, Naoto Okada et al. · 2022 · Clinical and Translational Science
29. Editorial: fenofibrate as second‐line therapy in high risk PBC – more answers or more questions?
    David E. Jones, Bettina E. Hansen · 2016 · Alimentary Pharmacology & Therapeutics
30. Primary biliary cholangitis: advances in understanding and management
    Alexander Smith, Benjamin Giles, Richard Aspinall · 2022 · British Journal of Hospital Medicine
31. Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies—A Critical Overview
    Beata Kasztelan‐Szczerbińska, Anna Rycyk, Agnieszka Szczerbińska, Halina Cichoż‐Lach · 2023 · Nutrients
32. Effect of Low Testosterone Levels on the Expression of Proliferator-Activated Receptor Alpha in Female Patients with Primary Biliary Cholangitis
    Agnieszka Kempińska‐Podhorodecka, Joanna Abramczyk, Eliza Cielica, Bartosz Huła, Hanna Maciejowska, Jesús M. Bañales, Piotr Milkiewicz, Małgorzata Milkiewicz · 2023 · Cells
33. Comparison of biliary protein spectrum in gallstone patients with obesity and those with normal body weight
    Minzhi Chen, Ping Xie, Xiaochang Wu, Zhenhua Tan, Hai Qian, Zhihong Ma, Xing Yao · 2023 · Hepatobiliary & pancreatic diseases international
34. Fibrates and Fibrate-induced Liver Injury in Primary Biliary Cholangitis
    Alessandra Vanasco, Eric vanSonnenberg · 2023 · Gene Expression
35. Advancing care in primary biliary cholangitis: emerging insights and novel therapies
    Vögelin, Marius, Kremer, Andreas E. · 2025 · Expert Opinion on Pharmacotherapy
36. Fermentable fibers induce rapid macro- and micronutrient depletion in Toll-like receptor 5-deficient mice
    Rachel M. Golonka, Beng San Yeoh, Yaqi Li, Piu Saha, Ahmed A. Abokor, Xi Cheng, Xia Xiao, Darshan Shimoga Chandrashekar, Sooryanarayana Varambally, David J. Gonzalez et al. · 2020 · American Journal of Physiology-Gastrointestinal and Liver Physiology
37. Seladelpar: a comprehensive review of its clinical efficacy and safety in the treatment of primary biliary cholangitis
    Ajay Kumar Shukla, Saurav Misra · 2025 · Journal of Basic and Clinical Physiology and Pharmacology
38. A comprehensive review of systemic sclerosis–primary biliary cholangitis overlap: emerging evidence for a distinct clinical subtype
    Areeka Memon, Manvitha Nadella, Morgan C. Emokpae, David N. Assis · 2025 · Current Opinion in Rheumatology
39. Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design
    Xinxue Wang, Jia Luo, Zhuoheng Lu, Shenzhe Fang, Mengxia Sun, Wenjing Luo, Jianwei Shen, Aiming Liu, Hua Ye · 2023 · Frontiers in Pharmacology
40. Ameliorative effect of curcumin and vitamin B6 against lithocholic acid-induced cholestasis and liver injury in mice
    MOHAMED ABDO NASSAN, Tamer Ahmed Ismail, Mohamed Mohamed Soliman, Adel Qlayel Alkhedaide · 2018 · Brazilian Journal of Veterinary Pathology
41. Quercetin mitigates liver injury in a rat model of liver cholestasis
    Noha A. Nassef, Ebtessam Abu-Shadi, Sahar Mohamed El Agaty, Gehad Abdel Hamid · 2020 · Bulletin of Egyptian Society for Physiological Sciences
42. T 1 – T 2 dual-modal magnetic resonance contrast-enhanced imaging for rat liver fibrosis stage
    Fulin Lu, Liang Du, Wei Chen, Hai Jiang, Chenwu Yang, Yu Pu, Jun Wu, Jiang Zhu, Tian‐wu Chen, Xiao Ming Zhang et al. · 2022 · RSC Advances
43. Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies
    Lili Xi, Axi Shi, Tiantian Shen, Guoxu Wang, Yuhui Wei, Jingjing Guo · 2023 · Frontiers in Pharmacology
44. Exploring the Potential Mechanisms of Action of Gentiana Veitchiorum Hemsl. Extract in the Treatment of Cholestasis using UPLC-MS/MS, Systematic Network Pharmacology, and Molecular Docking
    Yue Wang, Nixia Tan, Rong Su, Zhenhua Liu, Na Hu, Qi Zheng Dong · 2024 · Combinatorial Chemistry & High Throughput Screening
45. Cortex Dictamni induces cholestatic liver injury via the bile acid-gut-liver axis mediated by FXR signaling pathway in rats
    Xiaomin Xu, Fang Lü, Donghua Yu, Yu Wang, Pingping Chen, Wenkai Hu, Suxia Jia, Jiameixue Wo, Shumin Liu · 2025 · Journal of Ethnopharmacology
46. Progress and prospects of gut microbiota-targeted therapy for primary biliary cholangitis
    Xuan Rong Tang, Xin You · 2025 · Gut Pathogens
47. Numb-exon3 and full length Numb equivalently alleviate cholestatic liver fibrosis by inhibiting ductular reaction
    Yannan Xu, Meng-yao Zong, Wenping Xu, Shi-hao Zhang, Dan‐Yang Wang, Xin-rui Zheng, Fei-fei Xing, Jun-yi Zhan, Jiamei Chen, Gao‐Feng Chen et al. · 2025 · Scientific Reports
48. Cholestatic and autoimmune liver diseases, bile duct injury, oxidative stress, and therapeutic strategies
    Dominika Marta Stygar, Bartosz Bogielski, Katarzyna Michalczyk, Bronisława Skrzep-Poloczek, Alicja Suchocka, Kamil Nikiel, Kazimierz Kukla, Rafal Wasek, Jakub Staniszewski, Maciej Matyja et al. · 2026 · Frontiers in Physiology
49. Novel approach for reconstruction of the three-dimensional biliary system in decellularized liver scaffold using hepatocyte progenitors
    Kazuya Hirukawa, Hiroshi Yagi, Kohei Kuroda, Masafumi Watanabe, Kotaro Nishi, Shogo Nagata, Yuta Abe, Minoru Kitago, Shungo Adachi, Ryo Sudo et al. · 2024 · PLoS ONE
50. Uncovering the pharmacological mechanism and the main herbal medicine contributing to the efficacy of Xiaoyanlidan Tablet (XYLDT) in treating cholestatic liver injury
    Zeqi Wu, Jionghua Shi, Yue Zhang, Ruijia Shi, Qian Guo, Jingnan Zhang, Bin Lu, Zhenlin Huang, Lili Ji · 2024 · Journal of Ethnopharmacology
51. Emerging role of peroxisome proliferator-activated receptor agonists in the treatment of cholestatic liver disease
    Sheena R. Bhushan, Kris V. Kowdley · 2025 · Current Opinion in Gastroenterology
52. Protective effects of Polygonum cuspidatum bioactive constituents against cholestatic liver injury: A mechanistic review
    Zengni Zhang, Xiao Yang, Yan Fu, Huilin Wei, Yajuan Chen, Anlin Dai, Xia Zhou, Jun Wan, Wenwen Chen · 2025 · Fitoterapia
53. Primary biliary cholangitis: assessment and management strategies
    S Nadir Abbas, David E. Jones, Yiannis N. Kallis, Laura Maher, Imran Patanwala · 2021 · Gastrointestinal Nursing
54. Hepatic Aquaporin 10 Expression Is Downregulated by Activated NFκB Signaling in Human Obstructive Cholestasis
    Min Liao, Wenjing Yu, Qiaoling Xie, Liangjun Zhang, Qiong Pan, Nan Zhao, Ling Li, Ying Cheng, Xiaoxun Zhang, Dequn Sun et al. · 2022 · Gastro Hep Advances
55. Xiaohuang Qudan decoction alleviates ANIT-induced cholestatic liver injury by inhibiting the JAK2/STAT3 pathway and regulating TH17/Treg
    Zhangkui Tan, Lifeng Chen, Zhiqin Ye, Qiping Lu · 2025 · Chinese Journal of Natural Medicines
56. Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study
    Mariko Maxwell, Yanhong Deng, Bonnie Chen, Marina G. Silveira, James Lorenzen Boyer, David N. Assis · 2026 · Alimentary Pharmacology & Therapeutics
57. Microbiota in cholestatic diseases: crosstalk among bile composition, the biliary microbiome, and host immunity
    Yanni Yang, Longfei Ren, Yulin Zhang, Xiaojuan Wang, Jin Shang, Li Zhang · 2026 · Frontiers in Immunology
58. The Interaction of PPARα and CYP7B1 with ERα, β Impacted the Occurrence and Development of Intrahepatic Cholestasis in Pregnant Rats
    Zhaoyi Song, Qingyun Shi · 2016 · Reproductive Sciences
59. Microparticle formulations alter the toxicity of fenofibrate to the zebrafish Danio rerio embryo
    Indra Hering, Elke Eilebrecht, Michael John Parnham, Marc Weiler, Nazende Günday-Türeli, Akif Emre Türeli, Harshvardhan Modh, Paul Wan Sia Heng, Walter Böhmer, Christoph Schäfers et al. · 2021 · Aquatic Toxicology
60. Pathophysiologic Basis for Alternative Therapies for Cholestasis
    Claudia Daniela Fuchs, Emina Halilbasic, Michael A Trauner · 2020 · Wiley eBooks
61. CHOLESTASIS: MOLECULAR MECHANISM, PATHOGENESIS AND POSSIBLE MANAGEMENT
    Basant M. Al-Botaty · 2018 · Al-Azhar Journal of Pharmaceutical Sciences/Al-Azhar Journal of Pharmaceutical Sciences
62. IL-25 ameliorates acute cholestatic liver injury via promoting hepatic bile acid secretion
    Zewei Zhao, Siqi Liu, Shiya Luo, Lin Zhou, Junxi Liu, Bingxiu Qian, Jianglin Shi, Yayun Zhou, Jin Li, Tao Jiang et al. · 2022 · Cytokine
63. Macrophages-Mediated Liver Fibrosis: A Bibliometric Analysis
    Menglin Yao, Ting Wang, Tian-Peng Liu, Qi-Xin Zhao, Hongping Shen, Qin Sun · 2024 · Hepatitis Monthly
64. Fenofibrate in managing cholestatic pruritus in paediatric patients
    Jesús Quintero, Javier Juampérez, Cristina Padrós Fornieles, Mauricio Larrarte-King, Simone Mameli, Lis Vidal-Valdivia, Susana Clemente, Aurora Fernández-Polo, Jose Andrés Molino, María Mercadal‐Hally · 2025 · Annals of Hepatology
65. Taurochenodeoxycholic acid ameliorates liver fibrosis by regulating gut microbiota and bile acids via hippo-YAP pathway
    Lisheng Zhang, Yujing Li, Junyi Zhang, Ming Zhang, Wei Chen · 2025 · iScience
66. Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases
    Satoko Watanabe, Kyosuke Nagura, Naoto Okada, Taro Watanabe, Hidenori Sagara · 2025 · Frontiers in Pharmacology
67. The Personalized Management of Primary Biliary Cholangitis in the Era of Precision Medicine: Current Challenges and Future Perspectives
    Mario Romeo, Fiammetta Di Nardo, Claudio Basile, Carmine Napolitano, Paolo Vaia, Giuseppina Martinelli, Alessia De Gregorio, Luigi Di Puorto, Mattia Indipendente, Marcello Dallio et al. · 2025 · Journal of Personalized Medicine
68. Huang Qi Decoction inhibits differentiation of hepatic oval cells to cholangiocytes via the β-catenin pathway to ameliorate hepatic fibrosis
    Zhi-dong Liu, Ke-pei Zhang, Dan-yang Wang, Xiao Zhang · 2025 · Tissue and Cell
69. Lipidome remodeling in primary biliary cholangitis
    M. Rogalska, P. Rogalski, Aleksandra Andrzejuk, Agnieszka U. Błachnio-Zabielska, Piotrek Zabielski, R. Flisiak · 2026 · Lipids in Health and Disease
70. Isoastragaloside II modulates PPAR-α/FXR signaling and bile acid metabolism to ameliorate cholestatic liver diseases (CLD)
    Lan Luo, Wei Liu, Shenglan Qi, Jiamei Chen, Hua Zhang, 慕永平, Gaofeng Chen, Wei'an Yuan, Ping Liu, Linzhang Zhang · 2026 · European Journal of Pharmacology
71. Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis
    Ryohei Tanigawa, Yoshiyuki Ueno, Hirokazu Takahashi, Ayumi Saito, Hideki Suganami, Atsushi Tanaka · 2026 · Hepatology Research
72. In silico drug discovery of flavonoids as potential PPAR agonists in treatment of metabolic syndrome
    Bao Hoang Gia Nguyen, Phuong Chau Uyen Nguyen, Khoi Anh Nguyen, Phat Nguyen Pham, Phuong Thuy Viet Nguyen · 2023 · Pharmaceutical Sciences Asia
73. Lipid-lowering therapy for hypertriglyceridemia-induced acute pancreatitis: Recent advances
    Huimin Chen, Dong-Shuai Su, Hongyu Li, Xiaozhong Guo, Xingshun Qi · 2023 · World Chinese Journal of Digestology
74. Primary biliary cholangitis
    Juan Pablo Trivella, Cynthia Levy · 2024 · Elsevier eBooks
75. The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis
    Taimoor Ashraf, Omar Abunada, N. Seerani, Kashif Ali, Areej Muhammad, Syeda Lamiya Mir, Syed Adil Mir Shah, M. Hassaan, Vikash Kumar, Waseem Abbas et al. · 2025 · BMC Gastroenterology
76. Primary Biliary Cholangitis in Motion Meeting
    Lois Skellon · 2018 · EMJ Hepatology
77. Adaptive Regulation of Hepatocyte Transporters in Cholestasis
    James Lorenzen Boyer · 2020
78. Orphan drugs in development for primary biliary cirrhosis: challenges and progress
    Keith D. Lindor, Ahmad Hassan Ali, Thomas Byrne · 2015 · Orphan Drugs Research and Reviews
79. Biologie des maladies cholestatiques chroniques de l’adulte
    Sara Lemoinne, Olivier Chazouillères · 2017 · Revue Francophone des Laboratoires
80. Targets and investigative treatments for primary biliary cholangitis
    Ahmad Hassan Ali, Elizabeth J. Carey, Keith D. Lindor · 2016 · Expert Opinion on Orphan Drugs
81. Future Therapies for Primary Sclerosing Cholangitis
    Craig Steven Lammert, Raj Vuppalanchi · 2016 · Springer eBooks
82. Treatment of chronic cholestasis: What we know and what we will know?
    James Lorenzen Boyer · 2016 · Clinical Liver Disease
83. Advances in treatment options for patients with primary biliary cholangitis
    Albert Rodrigo Parés · 2017 · Expert Opinion on Orphan Drugs
84. Emerging therapeutic targets for primary sclerosing cholangitis
    Amir Kalani, James H. Tabibian, Keith D. Lindor · 2018 · Expert Opinion on Orphan Drugs
85. In primary biliary cholangitis, adding bezafibrate to ursodeoxycholic acid increased complete biochemical response
    Jacob Korula · 2018 · Annals of Internal Medicine
86. MECHANISMS OF INDIVIDUAL VARIATION IN GLUCURONIDATION, SULFONATION, AND AMIDATION: BISPHENOL A AND BILE ACIDS
    Adam Auclair · 2018
87. Un estudio controlado contra placebo sobre el uso de bezafibrato en colangitis biliar primaria
    Ignacio Bezama F., Sebastián González V., Nicolás Zañartu A., Andrés Soffia P., Pauline Böhm G., L. Díaz P., Francisco Barrera M. · 2020 · Revista Gastroenterología Latinoamericana
88. The Expression Changes of the Mcl-1 Gene Following Cholestasis and Treatment by Neuroaid in Striatum of Male Rats
    Sepehr Torabinejad, Mehrdad Hashemi, Mohammad Nasehi · 2019 · Medical Journal of Tabriz University of Medical Sciences and Health Services
89. Patients atteints de cholangite biliaire primitive et non répondeurs à l’acide urso-désoxycholique. Cas cliniques commentés
    Solange Bresson‐Hadni, Gérard Thiéfin · 2019 · HEGEL - HEpato-GastroEntérologie Libérale
90. Celastrol通过调制SIRT1-FXR信号传导来保护胆汁淤积肝损伤* [S]
    齐泽, 方刘, 闫成, 薛荣萧, 丹 丹胡, 莹梅唐, 魏民宝, 金辉杨, 陶江, 贾鹏胡 et al. · 2019
91. General Perspectives for the Treatment of Atherosclerosis
    Hayrettin Ozan Gülcan, İlkay Erdoğan Orhan · 2020 · Letters in Drug Design & Discovery
92. Screening and Validation of Novel Biomarkers for Cadmium‐Induced Liver Injury Based on Targeted Bile Acid Metabolomics1
    Meng Tian, Jun Yan, Honglong Zhang, Yuhui Wei, Mingtong Zhang, Zhi Rao, Mingkang Zhang, Haiping Wang, Yanping Wang, Xun� Li · 2021 · SSRN Electronic Journal
93. Parte IV. Efectos extralipídicos del fenofibrato
    2016 · Clínica e Investigación en Arteriosclerosis
94. Fenofibrate in a patient with primary biliary cholangitis with an inadequate response to bezafibrate
    Yangyang Y. Zhou, Haonan Gao, Yuhu Song · 2023 · Portal hypertension & cirrhosis
95. Is primary biliary cholangitis still a challenge? Experience of Hassan II University Hospital FES Morocco
    Imane ATMANI, María Lahlali, Asmae Lamine, Nada Lahmidani, Amine ElMekkaoui, Mounia El Yousfi, Dafrlah Benajah, Mohamed El Abkari, Adil Ibrahimi, Hakima Abid · 2024 · World Journal of Advanced Research and Reviews
96. Sesamol ameliorates cholestatic liver injury by modulating the liver-gut axis and EGFR-FXR signaling pathway
    Shasha Chen, Wenwen Li, Xinran Zhu, Yanlu Han, Mengyao Wang, Ke Qin Gong, Jie Xiao, Chenzhong Liao, Yajun Duan, Xiaohua Jiang et al. · 2025 · Food Bioscience
97. Neue Standards in der Behandlung der primären biliären Cholangitis
    Marius Vögelin, Andreas Emanuel Kremer · 2025 · Schweizer Gastroenterologie
98. Evolving paradigms in primary biliary cholangitis: from molecular mechanisms to personalized therapeutics with seladelpar, elafibranor, and beyond
    Bushra Qasim, Hina Kumari, Syeda Naveera Kashif, Syed Muhammad Iraj Abbas, Omme Hani, Omme Salma, Ahsan Sauleh, FNU Adnan, Mashooque Ali, Abdul Raheem et al. · 2025 · Egyptian Liver Journal
99. Investigation of alpha smooth muscle actin changes in the liver of cholestatic rats following the consumption of L-theanine
    Mobina Daneshnia, Pejman Mortazavi, Mahsa Ale‐Ebrahim, Razieh Hosseini · 2025 · Toxicology Reports
100. Additional file 1 of Dihydromyricetin ameliorated nonalcoholic steatohepatitis in mice by regulating the composition of serous lipids, bile acids and ileal microflora
     Miao, Xiaolei, Luo, Ping, Jiao Liu, Wang, Junjun, Chen, Yong · 2023 · Figshare